Chikungunya Virus Infection

A Phase I Study of PepGNP-ChikV in Healthy Volunteers

Xpert® Tropical Fever Test on GeneXpert® Edge X System

Against Chikungunya Virus and Neonatal Infection

VLA1553-403 Pregnancy Surveillance Study

Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil

Phase 1 Study of SAR440894 vs Placebo

A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years

Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion

Chikungunya Virus Detection in Semen

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases

A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)

Consequences of a Maternal-fetal Chikungunya Virus Infection

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults